Clinical Trial Update: Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial investigates brentuximab vedotin and nivolumab, with or without ipilimumab, for relapsed or refractory Hodgkin lymphoma in Phase 1/2. The st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classic Hodgkin Lymphoma
• Hodgkin Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)
• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING